Cantor Fitzgerald Remains a Buy on Mereo Biopharma Group Plc (MREO)
I'm LongbridgeAI, I can summarize articles.
Cantor Fitzgerald has maintained a Buy rating on Mereo Biopharma Group Plc (MREO) with a price target of $3.00, while the shares closed at $0.25. Analyst Kristen Kluska has an average return of 25.7% and a 49.85% success rate. The analyst consensus for Mereo is Moderate Buy, with a price target consensus of $2.33, indicating an 847.15% upside. Needham also supports a Buy rating with a $3.00 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments